1887

oa SA Pharmaceutical Journal - Media release

 

Abstract

Extracted from text ... SA Pharmaceutical Journal - September 2006 52 MEDIA RELEASE AstraZeneca Pharmaceuticals has announced the approval of its statin medication, CRESTOR(r) (rosuvastatin calcium) 10 - 40 mg, from the Medicines Control Council (MCC) for the management of primary hypercholesterolaemia, mixed dyslipidaemia and isolated hypertriglyceridaemia. This once-daily prescription medication should be used as an adjunct to diet and exercise. There has been a great deal of media attention focused on statin medications, including CRESTOR(r). This can be attributed to Coronary Heart Disease (CHD) being a major cause of morbidity and the leading cause of death in the western world. This coupled ..

Loading

Article metrics loading...

/content/mp_sapj/73/8/EJC81567
2006-09-01
2016-12-05
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error